A Phase 4 interventional study of Haloperidol, Risperidone (drug) in Schizophrenia, sponsored by Heinrich-Heine University, Duesseldorf. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2008-02-07.
Sponsored by Heinrich-Heine University, Duesseldorf · Phase 4, Interventional, and Treatment
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
The objective of this multi-center study is to optimize the long-term treatment of patients with first episode schizophrenia. This investigation should contribute to the issue of effective relapse prevention in first-episode patients. 1-year maintenance neuroleptic treatment is done with low dose haloperidol or risperidone (target dose 2-4 mg/die).
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 159 is above the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Heinrich-Heine University, Duesseldorf is the lead sponsor of 174 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Maintenance antipsychotic treatment with risperidone
Drug: Haloperidol, Risperidone (drug)
Maintenance antipsychotic treatment with haloperidol in low-dose
Drug: Haloperidol, Risperidone (drug)
targeted dose of 2-4 mg/day over 1 year
relapse rate
Time frame: 1 year
course in psychopathology
Time frame: 1 year
social and cognitive functioning
Time frame: 1 year
side-effects
Time frame: 1 year
drop-out
Time frame: 1 year
quality of life
Time frame: 1 year
This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heinrich-Heine University, Duesseldorf